{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:16:21Z","timestamp":1783462581300,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,5,12]],"date-time":"2009-05-12T00:00:00Z","timestamp":1242086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,5,12]],"date-time":"2009-05-12T00:00:00Z","timestamp":1242086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10637-009-9258-0","type":"journal-article","created":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T15:03:32Z","timestamp":1242054212000},"page":"502-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC Regimen)in advanced malignancies"],"prefix":"10.1007","volume":"28","author":[{"given":"Robert","family":"Wesolowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Peereboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Elson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thomas Budd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,5,12]]},"reference":[{"key":"9258_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2007.11.3787","volume":"26","author":"M De Laurentiis","year":"2008","unstructured":"De Laurentiis M, Cancello G, D'Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44\u201353. doi:10.1200\/JCO.2007.11.3787","journal-title":"J Clin Oncol"},{"key":"9258_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/1097-0142(19930115)71:2<392::AID-CNCR2820710220>3.0.CO;2-Y","volume":"71","author":"G Ellis","year":"1993","unstructured":"Ellis G, Livingstron RB (1993) Feasibility of dose-intensive continuous 5-FU, doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer. Cancer 71:392\u2013396. doi:10.1002\/1097-0142(19930115)71:2<392::AID-CNCR2820710220>3.0.CO;2-Y","journal-title":"Cancer"},{"key":"9258_CR3","first-page":"53","volume":"13","author":"GK Ellis","year":"1994","unstructured":"Ellis GK, Livingston RB (1994) Augmented dose intensity with concurrent G-CSF and continuous 5-FU. Adriamycin and cyclophosphamide chemotherapy for breast cancer. Proc ASCO. 13:53","journal-title":"Proc ASCO."},{"issue":"5","key":"9258_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00000421-199910000-00004","volume":"22","author":"GK Ellis","year":"1999","unstructured":"Ellis GK, Green S, Livingston RB et al (1999) 'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study. Am J Clin Oncol 22(5):446\u2013449. doi:10.1097\/00000421-199910000-00004","journal-title":"Am J Clin Oncol"},{"issue":"18S","key":"9258_CR5","first-page":"LBA537","volume":"24","author":"GK Ellis","year":"2006","unstructured":"Ellis GK, Green SJ, Russell CA et al (2006) SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol, 2006 Proceedings of ASCO 24(18S):LBA537","journal-title":"J Clin Oncol, 2006 Proceedings of ASCO"},{"key":"9258_CR6","first-page":"189a","volume":"17","author":"NW Peacock","year":"1998","unstructured":"Peacock NW, Burns HA, Hainsworth JD et al (1998) Weekly docetaxel in patients with advanced refractory malignancies; a phase I trial. Proc ASCO. 17:189a","journal-title":"Proc ASCO."},{"key":"9258_CR7","first-page":"113a","volume":"17","author":"TM Loffler","year":"1998","unstructured":"Loffler TM, Freund W, Droge C et al (1998) Activity of weekly taxotere in patients with metastatic breast cancer. Proc ASCO. 17:113a","journal-title":"Proc ASCO."},{"key":"9258_CR8","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","volume":"13","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Burris HA III, Cook G et al (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879\u20132885","journal-title":"J Clin Oncol"},{"key":"9258_CR9","first-page":"115","volume":"15","author":"P Ravdin","year":"1996","unstructured":"Ravdin P, Valero V, Nabholz J-M et al (1996) Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere induced fluid retention. Proceedings of ASCO [Abstract 124] 15:115","journal-title":"Proceedings of ASCO [Abstract 124]"},{"issue":"22","key":"9258_CR10","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302\u20132313. doi:10.1056\/NEJMoa043681","journal-title":"N Engl J Med"},{"issue":"13","key":"9258_CR11","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24(13):2019\u20132027. doi:10.1200\/JCO.2005.04.1665","journal-title":"J Clin Oncol"},{"issue":"6","key":"9258_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976\u2013983. doi:10.1200\/JCO.2003.02.063","journal-title":"J Clin Oncol"},{"issue":"16","key":"9258_CR13","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky B (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23(16):3686\u20133696. doi:10.1200\/JCO.2005.10.517","journal-title":"J Clin Oncol"},{"issue":"5","key":"9258_CR14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.1995.13.5.1152","volume":"13","author":"AD Seidman","year":"1995","unstructured":"Seidman AD, Reichman BS, Crown JP et al (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13(5):1152\u20131159","journal-title":"J Clin Oncol"},{"issue":"22","key":"9258_CR15","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302\u20132313. doi:10.1056\/NEJMoa043681","journal-title":"N Engl J Med"},{"issue":"5","key":"9258_CR16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/TCRM.S3397","volume":"4","author":"L Palmeri","year":"2008","unstructured":"Palmeri L, Vaglica M, Palmeri S (2008) Weekly docetaxel in the treatment of metastatic breast cancer. Ther Clin Risk Manage 4(5):1047\u20131059","journal-title":"Ther Clin Risk Manage"},{"issue":"16","key":"9258_CR17","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S et al (2008) Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N Engl J Med 358(16):1663\u20131671. doi:10.1056\/NEJMoa0707056","journal-title":"N Engl J Med"},{"issue":"11","key":"9258_CR18","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Munzone E, Capri G et al (1995) Paclitaxel by 3-Hour Infusion in Combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13(11):2688\u20132699","journal-title":"J Clin Oncol"},{"key":"9258_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1023\/B:BREA.0000025405.63953.f9","volume":"85","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Green SJ, Ravdin PM et al (2004) A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. Breast Cancer Res Treat 85:143\u2013150. doi:10.1023\/B:BREA.0000025405.63953.f9","journal-title":"Breast Cancer Res Treat"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9258-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9258-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9258-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:37:41Z","timestamp":1678509461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9258-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["9258"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9258-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,12]]},"assertion":[{"value":"24 February 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}